ArticleEuropean journal of medical research2025
Development of the G-Risk scoring system utilizing inflammatory and tumor biomarkers to improve prognostic accuracy in gastric cancer patients without lymphovascular invasion.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to establish the G-Risk scoring system, a prognostic model based on inflammatory and tumor biomarkers, to enhance survival predictions for gastric cancer patients without lymphovascular invasion (LVI) and guide more tailored treatment strategies.
methodsThe key biomarkers associated with survival outcomes were identified using univariate and multivariate Cox regression analyses. These biomarkers were selected from a range of inflammatory and tumor markers to construct the G-Risk scoring system, which was specifically developed to improve prognostic accuracy in patients without LVI.
resultsThe G-Risk score effectively stratified patients into high-risk and low-risk groups, achieving an AUC of 0.660, demonstrating strong predictive performance. Further multivariate analysis validated the G-Risk score as an independent prognostic factor with significant implications for patient survival.
conclusionThe G-Risk score was successfully developed and validated as a reliable prognostic tool for gastric cancer patients without LVI. Its clinical implementation offers enhanced precision in assessing prognostic risk, facilitating personalized treatment planning, improving therapeutic outcomes, and reducing unnecessary medical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.